Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060915 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2MDM2SLC17A5MDM4TP53 | |
| SCHEMBL5274394 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2MDM2SLC17A5MDM4TP53 | |
| SCHEMBL31144246 | 0.90 | MDM2 (0.46) | MDM2MDM4TP53CASP3 | |
| SCHEMBL30393072 | 0.89 | SLC17A5 (0.51) | MDM2SLC17A5MDM4TP53CASP3 | |
| SCHEMBL5056936 | 0.89 | SLC17A5 (0.51) | MDM2SLC17A5MDM4TP53CASP3 | |
| SCHEMBL5056933 | 0.89 | SLC17A5 (0.51) | MDM2SLC17A5MDM4TP53CASP3 | |
| SCHEMBL5065049 | 0.88 | MDM2 (0.45) | MDM2MDM4TP53CASP3 | |
| SCHEMBL5060938 | 0.88 | KMT2A (0.51) | SLC17A5MDM4TP53CASP3CASP1 | |
| SCHEMBL29624261 | 0.86 | SLC17A5 (0.49) | MDM2SLC17A5MDM4TP53CASP3 | |
| SCHEMBL29987626 | 0.86 | CASP3 (0.46) | SMN1; SMN2MDM2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004290-A1 | Anti-Cancer Agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004290-A1 | Anti-Cancer Agents | TP53, TOP2A, MCL1 | SMN1; SMN2 3813/4885MDM2 1432/4885SLC17A5 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.